NCT07365410 2026-01-26Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety StudyTianjin Medical University Cancer Institute and HospitalPhase 2 Not yet recruiting60 enrolled